Tozumab Alleviates Doxorubicin-induced Myocardial Cell Injury through the cGAS STING Pathway

doi:10.3870/j.issn.1672-0741.25.07.040

Abstract

Abstract: Objective This study aimed to explore the protective effect of tocilizumab on acute myocardial injury induced by doxorubicin. Methods Human AC16 cardiomyocytes were treated with different concentrations of tocilizumab(1,3,and 5 μg/mL)before exposure to doxorubicin(1 μmol/L).Cell viability was assessed using the CCK-8 assay,while apoptosis was measured by flow cytometry.The ROS level was assessed with a DCFH2-DA probe.JC-1 staining was used to analyze the mitochondrial membrane potential.The expression levels of CXCL10,STING,and cGAS were detected through Western blotting and qRT-PCR. Results In the context of the cytotoxicity induced by doxorubicin,tocilizumab significantly increased AC16 cell viability(P<0.01)and reduced early and late apoptosis rates(P<0.01).In addition,tocilizumab reduced the ROS level(P<0.01)and downregulated the expression of cGAS,STING and CXCL10. Conclusion Tocilizumab has a cardioprotective effect on doxorubicin-induced myocardial injury by modulating the cGAS-STING pathway,highlighting its potential as a therapeutic agent to improve cardiac safety during chemotherapy.

Key words: tocilizumab, acute myocardial injury, doxorubicin, apoptosis

CLC Number:

R542.2

Zhai Fuqiang, Bi Xiufeng, An Xiaotong et al. Tozumab Alleviates Doxorubicin-induced Myocardial Cell Injury through the cGAS STING Pathway[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2026, 55(1): 91-96.

References

[1] Gunata M,Parlakpinar H.A review of myocardial ischaemia/reperfusion injury:pathophysiology,experimental models,biomarkers,genetics and pharmacological treatment[J].Cell Biochem Funct,2021,39(2):190-217.
[2] 常文慧,张艳丽,刘子宁,等.阿霉素通过循环肿瘤细胞介导三阴性乳腺癌转移[J].华中科技大学学报:医学版,2021,50(5):585-591.
Chang W H,Zhang Y L,Liu Z N,et al.Doxorubicin mediates triple negative breast cancer metastasis through circulating tumor cells[J].Acta Med Univ Sci Technol Huazhong,2021,50(5):585-591.
[3] Ibrahim A A,Nsairat H,Al-Sulaibi M,et al.Doxorubicin conjugates:a practical approach for its cardiotoxicity alleviation[J].Expert Opin Drug Deliv,2024,21(3):399-422.
[4] Roberto A,Emilio J,Carlo C.Pathophysiology of doxorubicin-mediated cardiotoxicity[J].Toxics,2025,13(4):277-292.
[5] 戴婷,徐亚宁,谌赟,等.亚精胺通过miR-451介导自噬缓解阿霉素诱导的心肌细胞衰老[J].华中科技大学学报:医学版,2024,53(6):791-795.
Dai T,Xu Y N,Chen Y,et al.Spermidine mediates autophagy through miR-451 toalleviate adriamycin-induced cardiomyocyte senescence[J].Acta Med Univ Sci Technol Huazhong,2024,53(6):791-795.
[6] Shi S X,Chen Y,Luo Z J,et al.Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy[J].Cell Commun Signal,2023,21(1):61-80.
[7] Oduro P K,Zheng X X,Wei J N,et al.The cGAS-STING signaling in cardiovascular and metabolic diseases:future novel target option for pharmacotherapy[J].Acta Pharm Sin B,2022,12(1):50-75.
[8] Wan X Q,Tian J F,Hao P,et al.The cGAS-STING pathway:A ubiquitous checkpoint perturbing myocardial attributes[J].Curr Vasc Pharmacol,2023,21(3):152-162.
[9] Hu L F,Lan H R,Li X M,et al.A systematic review of the potential chemoprotective effects of resveratrol on doxorubicin-induced cardiotoxicity:Focus on the antioxidant,antiapoptotic,and antiatic review of the poten[J].Oxid Med Cell Longev,2021,2021(1):2951697.
[10] Rawat P S,Jaiswal A,Khurana A,et al.Doxorubicin-induced cardiotoxicity:An update on the molecular mechanism and novel therapeutic strategies for effective management[J].Biomed Pharmacother,2021,139:111708.
[11] Simone P,Maria Chiara D,Francesco G,et al.Update on tocilizumab in rheumatoid arthritis:A narrative review[J].Front Immunol,2025,16:1470488.
[12] Sujin K,Tadamitsu K.Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms[J].Exp Mol Med,2021,53(7):1116-1123.
[13] Valentina S,Annunziatina L,Valentina B,et al.Interleukin-6 modulates the expression and function of HCN channels:A link between inflammation and atrial electrogenesis[J].Int J Mol Sci,2024,25(22):12212.
[14] Davide M C,Stefan W,Fabio S,et al.Tocilizumab reduces vasospasms,neuronal cell death,and microclot formation in a rabbit model of subarachnoid hemorrhage[J].Transl Stroke Res,2021,12(5):894-904.
[15] Cappetta D,De Angelis A,Sapio L,et al.Oxidative stress and cellular response to doxorubicin:A common factor in the complex milieu of anthracycline cardiotoxicity[J].Oxid Med Cell Longev,2017,2017:1521020.
[16] Liu H T,Zhang Y,Wu Z H,et al.Identification of IL-6 as a potential mediator of the myocardial fibrosis that occurs in response to surgery with cardiopulmonary bypass in children with Tetralogy of Fallot[J].Cardiol Young,2021,32(2):223-229.
[17] George M J,Kleveland O,Garcia-Hernandez J,et al.Novel insights into the effects of interleukin 6 antagonism in non-st-segment-elevation myocardial infarction employing the SOMAscan proteomics platform[J].J Am Heart Assoc,2020,9(12):e015628.
[18] Wassmann S,Stumpf M,Strehlow K,et al.Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensinⅡtype 1 receptor[J].Circ Res,2004,94(4):534-541.
[19] Kaspar B,Anne Kristine A,Sindre W,et al.Randomized trial of interleukin-6 receptor inhibition in patients with acute st-segment elevation myocardial infarction[J].J Am Coll Cardiol,2021,77(15):1845-4855.
[20] Wu X G,Tang L,Huang W,et al.Membrane protein of SARS-CoV-2 promotes the production of CXCL10 and apoptosis of myocardial cells[J].Cardiovasc Toxicol,2025,25(6):830-840.
[21] Du Y,Zhang H,Nie X Y,et al.Link between sterile inflammation and cardiovascular diseases:Focus on cGAS-STING pathway in the pathogenesis and therapeutic prospect[J].Front Cardiovasc Med,2022,9:965726.
[22] Zhang Q X,Shen L J,Ruan H B,et al.cGAS-STING signaling in cardiovascular diseases[J].Front Immunol,2024,15:1402817.
[23] Ruiz-Limon P,Ortega R,de la Rosa I A,et al.Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction,NETosis,and inflammation[J].Transl Res,2017,183(0):87-103.
[24] Arjen J C,Folkert W A,Pradeep N,et al.Dissecting the IL-6 pathway in cardiometabolic disease:A Mendelian randomization study on both IL6 and IL6R[J].Br J Clin Pharmacol,2021,88(6):2875-2884.